Braveheart Bio, Inc.
Braveheart Bio develops BHB-1893, an oral small-molecule cardiac myosin inhibitor for obstructive and non-obstructive hypertrophic cardiomyopathy.
SCHEDULE 13GNov 16Latest SEC filing
Nov 10Latest story
November 2026
October 2026
September 2026
August 2026
July 2026